Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

VEGF 165 (Homodimer) (Active) Protein

Origin: Human Host: Escherichia coli (E. coli) Recombinant > 95 % by SDS-PAGE. Visualized by silver stain Active
Catalog No. ABIN1589678
  • Target
    VEGF 165
    Protein Type
    Recombinant
    Biological Activity
    Active
    Protein Characteristics
    Homodimer
    Origin
    • 20
    • 3
    • 2
    Human
    Source
    • 12
    • 7
    • 2
    • 1
    • 1
    • 1
    • 1
    Escherichia coli (E. coli)
    Sequence
    APMAEGGGQN HHEVVKFMDV YQRSYCHPIE TLVDIFQEYP DEIEYIFKPS CVPLMRCGGC CNDEGLECVP TEESNITMQI MRIKPHQGQH IGEMSFLQHN KCECRPKKDR ARQENPCGPC SERRKHLFVQ DPQTCKCSCK NTDSRCKARQ LELNERTCRC DKPRR
    Characteristics
    Length (AA): 164
    Chromosomal location: 6p12
    The ED50 for stimulation of cell proliferation in human umbilical vein endothelial cells by VEGF165 has been determined to be in the range of 1-5 ng/mL.
    Purity
    > 95 % by SDS-PAGE. Visualized by silver stain
    Endotoxin Level
    < 0.1 ng per µg of human VEGF165
  • Comment

    Cytokines & Growth Factors

    Restrictions
    For Research Use only
  • Format
    Lyophilized
    Reconstitution
    The lyophilized VEGF165 should be reconstituted in 50 mM acetic acid to a concentration not lower than 50 μg/mL. For long term storage we recommend to add at least 0.1% human or bovine serum albumin.
    Buffer
    50 mM acetic acid
    Storage
    -20 °C/-80 °C
    Storage Comment
    Lyophilized samples are stable for greater than six months at -20 °C to -70 °C. Reconstituted VEGF165 should be stored in working aliquots at -20 °C.
    Expiry Date
    6 months
  • Gaumann, Drexler, Lang, Stoeltzing, Diermeier-Daucher, Buchdunger, Wood, Bold, Breier: "The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®)." in: International journal of oncology, Vol. 45, Issue 6, pp. 2267-77, (2014) (PubMed).

  • Target
    VEGF 165
    Alternative Name
    VEGF165
    Background
    Human Vascular Endothelial Growth Factor VEGF165, a 23 kDa protein consisting of 165 amino acid residues, is produced as a homodimer. VEGF is a polypeptide growth factor and a member of the platelet-derived growth factor family. It is a specific mitogen for vascular endothelial cells and a strong angiogenic factor in vivo. Two high-affinity tyrosine kinase receptors for VEGF165 have been identified, VEGFR-1 (FLT-1), and VEGFR-2 (KDR). Consistent with the endothelial cell-specific action of VEGF165, expression of both receptor genes has been found predominantly but not exclusively on endothelial cells. Expression of VEGFR-1 was also found on human monocytes, neutrophils (PMNs), bovine brain pericytes and villous and extra villous trophoblast. In addition to its action as a mitogen it is a potent vascular permeability factor (VPF) in vivo. VEGF165 is also a chemo attractant molecule for monocytes and endothelial cells. 5 different proteins are generated by differential splicing: VEGF121, VEGF145, VEGF165, VEGF189 and VEGF206. The most abundant form is VEGF165. Whereas VEGF121 and VEGF165 are secreted proteins, VEGF145, VEGF189 and VEGF206 are strongly cell-associated. The isoforms VEGF145, VEGF165 and VEGF189 bind to heparin with high affinity. VEGF165 is apparently a homo-dimer, but preparations of VEGF165 show some heterogeneity on SDS gels, depending on the secretion of different glycosylation patterns. All dimeric forms have similar biological activities but their bioavailability is very different. There is good evidence that different cells and tissues express different VEGF isoforms. The other members of this increasing growth factor family are VEGF-B, -C, -D and -E. Another member is the Placenta growth factor PlGF.
    Synonyms: vascular endothelial growth factor A, VEGFA, VPF, VEGF, MVCD1
    Molecular Weight
    38.2 kDa
    NCBI Accession
    NM_001171626, NP_001165097
    UniProt
    P15692
You are here:
Support